Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation, doing business as NPS, is a foreign-owned pharmaceutical manufacturer supplying specialty oncology drugs and radiopharmaceuticals to the federal government as a prime contractor, competing without small business set-asides across full-and-open procurements. Headquartered in East Hanover, New Jersey, Novartis operates under primary NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC category Drugs and Biologicals, with a federal footprint dominated by the Department of Veterans Affairs and the Defense Health Agency.

Novartis's recent federal work centers on four core therapeutic products: PLUVICTO (Lutetium Lu-177 Vipivotide Tetra, a radiopharmaceutical for metastatic castration-resistant prostate cancer), LUTATHERA (Lutetium Lu-177 dotatate, for neuroendocrine tumors), FABHALTA (an oral immunosuppressant), and NETSPOT (a diagnostic radiopharmaceutical for neuroendocrine tumor imaging). Representative recent awards include a $4.98 million delivery order from Veterans Integrated Service Network 22 (VISN 22) for PLUVICTO (January 2, 2026), a $4.73 million delivery order from VISN 8 for PLUVICTO (February 24, 2026), a $3.4 million delivery order from VISN 21 for LUTATHERA (October 1, 2025), and a $617.3 thousand delivery order from VISN 10 for PLUVICTO with a completion date in this month (July 1, 2026). Novartis also supplies equipment services; a $402.6 thousand purchase order from the Defense Health Agency (August 15, 2025) covered service maintenance for a dental compressor at a TRICARE clinic.

Customer concentration is extreme: VISN 12 alone accounts for 69 awards with $23.87 billion in combined potential value, representing 98% of the vendor's total potential-value footprint. The Department of Veterans Affairs National Acquisition Center contributes $178.8 million across four awards, and the Defense Health Agency adds $39.2 million across eight awards. VISN 10 trails at $14 million across 15 awards. This concentration reflects Novartis's seat on the VA's primary oncology procurement vehicle—the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB)—which anchors most of the company's federal business. The Defense Logistics Agency, while placing 208 delivery orders, generates minimal dollar value compared to the VA's specialty pharmaceutical spend.

Novartis holds four major indefinite delivery vehicles. The Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) itself is a multi-billion-dollar vehicle on which Novartis places 876 task orders with $102.3 million combined potential value. More significantly, Novartis holds three single-award blanket purchase agreements: a $61.1 million BPA awarded by the National Acquisition Center on October 2, 2025 (through October 1, 2026) for KYMRIAH, FABHALTA, NETSPOT, and LOCAMETZ under 2026 Public Law pricing; a $7.48 million BPA awarded by VISN 10 on October 1, 2025 (through September 30, 2030) for PLUVICTO, which has already generated $1.16 million in a single delivery order; and a $5.0 million BPA awarded by the Defense Health Agency on March 2, 2026 (through February 9, 2031) for PLUVICTO and LUTATHERA. Novartis also holds a $26.1 million single-award Indefinite Delivery Contract with the Defense Health Agency (October 1, 2024 through September 30, 2029) for LUTATHERA and PLUVICTO, which has generated multiple delivery orders across fiscal years 2025 and 2026 totaling $3.39 million and $3.18 million respectively, with performance centered at Fort Sam Houston, Texas.

Activity has accelerated sharply: four awards in 2021 to 35 in 2025, with 23 awards in 2026 year-to-date. The portfolio carries $24.41 billion in combined potential value, though only $108.3 million (0.4%) has been obligated. Twenty-six awards face ultimate completion within the next twenty-four months with combined potential value of $40.9 million, creating near-term recompete exposure in both the VISN 10 PLUVICTO BPA and the National Acquisition Center four-drug BPA. Novartis maintains no visible subcontractor footprint in the source data; all 1,313 awards are prime contracts. Place of performance spans multiple Novartis facilities including East Hanover, New Jersey (headquarters and primary manufacturing), Cary, North Carolina, Lake Mary, Florida, Phoenix, Arizona, Lebanon, Pennsylvania, Chicago, Illinois, San Antonio, Texas, West Haven, Connecticut, and Bethesda, Maryland, supporting nationwide VA and Defense Health Agency distribution.